Biopharmaceuticals



During development and manufacture, protein therapeutics are monitored for several critical quality attributes (CQAs) to ensure the efficacy and safety for use of these complex, heterogenous biopharmaceuticals. One of the most important CQAs is aggregation. Understanding and controlling aggregation in therapeutic proteins, such as monoclonal antibodies (mAb), is essential; aggregation can impac...